Canaccord Genuity Maintains Hold on Pliant Therapeutics, Lowers Price Target to $3

Benzinga Newsdesk www.benzinga.com Negative 82.6%

Neg 82.6% Neu 0% Pos 0%

Canaccord Genuity analyst Edward Nash maintains Pliant Therapeutics (NASDAQ:PLRX) with a Hold and lowers the price target from $4 to $3.